Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Nexalin Technology Inc (NXLIW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: NXLIW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Year Target Price $0
Year Target Price $0
| 0 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit 15.71% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 4.05 | 52 Weeks Range 0.05 - 0.78 | Updated Date 06/17/2025 |
52 Weeks Range 0.05 - 0.78 | Updated Date 06/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -4903.63% |
Management Effectiveness
Return on Assets (TTM) -189.48% | Return on Equity (TTM) -367.74% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 14715129 |
Shares Outstanding - | Shares Floating 14715129 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Nexalin Technology Inc
Company Overview
History and Background
Nexalin Technology Inc. is a medical device company focused on developing and commercializing innovative neurostimulation technologies. Founded with the goal of providing non-invasive treatments for mental health disorders, it has focused on research, development, and clinical trials to support regulatory approvals and market adoption.
Core Business Areas
- Neurostimulation Devices: Development and commercialization of non-invasive neurostimulation devices utilizing frequency-based transcranial alternating current stimulation (tACS) technology. These devices are designed to address mental health issues.
- Clinical Research: Conducting clinical trials to demonstrate the safety and efficacy of Nexalin's devices and to expand the indications for their use.
Leadership and Structure
Nexalin Technology Inc.'s leadership team comprises experienced executives in the medical device and pharmaceutical industries. The organizational structure consists of departments focused on research and development, clinical affairs, regulatory affairs, manufacturing, and commercialization.
Top Products and Market Share
Key Offerings
- Nexalin Gen-1: The first generation neurostimulation device. Limited market share data available, as market penetration is in the early stages. Competitors include transcranial magnetic stimulation (TMS) devices (e.g., from Neuronetics (STIM)) and electroconvulsive therapy (ECT).
- Nexalin Gen-2: An enhanced neurostimulation device with improved features and clinical outcomes. Limited market share data available, as market penetration is in the early stages. Competitors include transcranial magnetic stimulation (TMS) devices (e.g., from Neuronetics (STIM)) and electroconvulsive therapy (ECT).
Market Dynamics
Industry Overview
The neuromodulation market is experiencing significant growth, driven by increasing prevalence of mental health disorders, technological advancements, and demand for non-pharmacological treatment options.
Positioning
Nexalin Technology Inc. is positioned as a provider of non-invasive neurostimulation technology offering a potentially safer and more convenient alternative to existing treatments like TMS and ECT.
Total Addressable Market (TAM)
The global neuromodulation market is estimated to reach billions of dollars. Nexalin is positioned to capture a portion of the TAM through its innovative technology and clinical data.
Upturn SWOT Analysis
Strengths
- Non-invasive technology
- Potential for improved patient outcomes
- Experienced management team
- Proprietary technology
Weaknesses
- Limited market penetration
- Reliance on clinical trial results
- Small company size
- Dependence on external funding
Opportunities
- Expansion of indications for use
- Partnerships with healthcare providers
- Increased awareness of neuromodulation therapies
- International market expansion
Threats
- Competition from established players
- Regulatory hurdles
- Reimbursement challenges
- Technological advancements by competitors
Competitors and Market Share
Key Competitors
- STIM
- MDLZ
- Abbott (ABT)
Competitive Landscape
Nexalin Technology Inc. faces significant competition from established medical device companies with greater resources and broader product portfolios. Its competitive advantage lies in its proprietary non-invasive technology.
Growth Trajectory and Initiatives
Historical Growth: Limited historical growth due to the early stage of commercialization.
Future Projections: Future growth projections depend on successful clinical trials and regulatory approvals. Analyst estimates anticipate revenue growth in the coming years.
Recent Initiatives: Recent initiatives include clinical trial enrollment, regulatory submissions, and market expansion efforts.
Summary
Nexalin Technology Inc. is an early-stage medical device company with a focus on neurostimulation. Its success hinges on clinical trial outcomes and regulatory approvals. While the company has potential due to its non-invasive technology, it faces significant competition and financial risks. Investors should monitor clinical trial results, regulatory approvals, and market adoption rates.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Nexalin Technology Inc. SEC filings
- Market research reports on neuromodulation
- Analyst reports on medical device companies
- Company press releases and investor presentations
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Investment decisions should be made after conducting thorough research and consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Nexalin Technology Inc
Exchange NASDAQ | Headquaters Houston, TX, United States | ||
IPO Launch date 2022-09-16 | President, CEO, CFO & Director Mr. Mark White | ||
Sector Healthcare | Industry Medical Devices | Full time employees 6 | Website https://www.nexalin.com |
Full time employees 6 | Website https://www.nexalin.com | ||
Nexalin Technology, Inc. designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy. It also offers Generation 2 and Generation 3 headset devices for the treatment of depression, substance use disorder, traumatic brain injury, post-traumatic stress disorder, opioid addiction, alcoholism, and chronic pain, as well as alzheimer's disease, and dementia. The company was incorporated in 2010 and is headquartered in Houston, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.